Navigation Links
Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate

CAMBRIDGE, Mass., June 18, 2007 - Genzyme Corp. (Nasdaq: GENZ) today announced the results of two new studies comparing a powder form of Renvela™ (sevelamer carbonate) to Renagel® tablets (sevelamer hydrochloride), including one trial in which patients received the powder form three times per day, and one in which it was administered once per day.

Genzyme is developing Renvela in powder form to provide an additional option for patients with chronic kidney disease in managing their phosphate levels. A New Drug Application for Renvela tablets is already on file with the FDA, and previous studies have shown that the tablet formulation provides equivalent phosphate control to Renagel in patients on dialysis and significant phosphorus control in patients with chronic kidney disease who are not on dialysis. Today’s results are the first from trials comparing the efficacy of the powder form of Renvela to Renagel tablets.

In the first powder trial, patients treated with the powder form of Renvela three times per day experienced equivalent phosphorus control to patients treated with Renagel tablets three times per day. As a result, this trial successfully met its primary endpoint.

In the second trial, patients dosed with the powder form of Renvela once per day and those treated with Renagel tablets three times per day achieved statistically significant reductions in serum phosphorus, with both groups reaching target levels for phosphorus control outlined in the K/DOQI treatment guidelines. Phosphorus levels in the Renagel arm (4.6 mg/dL) were lower than those in the Renvela arm (5.3 mg/dL), and this trial did not achieve its primary endpoint of demonstrating non-inferiority of Renvela powder dosed once per day to Renagel tablets dosed three times per day.

In both trials, the safety profile of Renvela was consistent with the previous clinical experience of patients on dialysis
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/22/2014)... Sept. 22, 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... to present a corporate overview and update at the ... 26, 2014, at 11:30 a.m. Eastern Time (8:30 a.m. ... New York City . A ... under the investor relations section of Arena,s website at ...
(Date:9/22/2014)... -- According to the new market ... Media and Reagents), by Source, by type, by ... Testing, Research, Drug Discovery) - Analysis & Global ... studies the major market drivers, threats, opportunities, and ... tables and 64 figures spread through 225 pages ...
(Date:9/22/2014)... 22, 2014 CytRx Corporation (Nasdaq: ... in oncology, today announced that study designs and progress ... aldoxorubicin, a pivotal global Phase 3 clinical trial in ... 2b clinical trial in small cell lung cancer, will ... (ESMO) 2014 Congress being held September 26-30, in ...
Breaking Medicine Technology:Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6
... Texas--(BUSINESS WIRE)--May 15, 2007 - Reata,Pharmaceuticals, Inc. today ... 2007 issue of the journal Cancer Research showing ... for cancer,was highly effective in a rigorous animal ... signaling activity of STAT3, an,important target for new ...
... Presented at the Society for Investigative,Dermatology, FREEPORT, N.Y., ... new clinical research that the,8-oxo-guanine DNA glycosylase (OGG1) ... and TNF-alpha in UV,irradiated skin cells. The data ... Society for Investigative Dermatology, May 9 - 12,in ...
Cached Medicine Technology:RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds,Significant Promise for Treating Breast Cancer 2RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds,Significant Promise for Treating Breast Cancer 3AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1,Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV,Irradiated Skin Cells 2
(Date:9/22/2014)... A surprising new study pulls back the curtain on ... differences in payment and income between physicians who perform ... , Contrary to perception, the research indicates, the physician ... and other procedure-performing doctors. , The new findings counter ... pay per minute explains why doctors who perform procedures ...
(Date:9/22/2014)... Mozes HealthDay Reporter MONDAY, ... American parents are aware of online physician-rating sites, and more ... their children, according to a new national study. The ... -- further suggest that negative online ratings may dissuade parents ... recommended by a neighbor. Conversely, a positive online rating ...
(Date:9/22/2014)... South Asians living in Canada have a higher rate ... compared with while people, McMaster researchers have found. ... Canadian Medical Association Journal (CMAJ Open) and may ... the fastest-growing ethnic groups in the country is the ... Canada, comprising about three percent of the population. They ...
(Date:9/22/2014)... researchers have published a pilot study showing the ... people with multiple sclerosis (MS). Improvements were ... and pain. "Development and effectiveness of a ... Description and outcomes" was epublished ahead of print ... of MS Care (doi: 10.7224/1537-2073.2013-045). The authors ...
(Date:9/22/2014)... Two new prescription devices approved by the U.S. Food ... people with migraine headaches who don,t tolerate migraine medications ... -- the Cefaly -- is designed to prevent migraines, ... meant to be used when migraines first start, according ... looking for alternative migraine treatments. Because these devices aren,t ...
Breaking Medicine News(10 mins):Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 2Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 3Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Noninvasive Devices May Help Migraines, FDA Says 2
... from several misconceptions that people had about aging. A popular ... the happiest days of people's lives occur when they're young ... ,While old age was equated with unhappiness for other people, ... their old age. In other words older people seem to ...
... it is evident that a man is very critical and is ... and is admitted// in a Shenzhen hospital. It is very evident ... SAR's Centre for Health Protection said that the victim lives in ... a Hong Konger residing in Shenzhen. He fell ill after he ...
... and figures seemingly indicate that the number of violent ... over the past year//. According to the figures that ... shows that the staff had reported 224 incidents of ... ,Unison an organization that represents the health workers, says ...
... Cancer researchers in UK exclaimed children now become fond of ... meat// and fish – after surveying about 200 pairs of ... strong in high-protein dishes such as beef, lamb, fish, bacon ... to taste vegetables and dessert more preferably. ,Mothers ...
... According to the study it was found that Implantable ... //. But they are very efficient in reducing the ... published in the American Heart Association rapid access journal ... were sicker and more prone to develop heart failure,’ ...
... seizures, or psychogenic seizures are often misdiagnosed as epileptic ... epilepsy is caused by the abnormal electrical activity in ... are similar to epileptic seizures, they can be difficult ... 13, 2006, issue of Neurology, the scientific journal of ...
Cached Medicine News:Health News:Attitudes About Aging Different from Reality 2Health News:Attitudes About Aging Different from Reality 3Health News:Violence Against NHS Staff On The Raise 2Health News:Defibrillators Can Only Put off Heart Failure but Cannot Prevent One 2Health News:Clues To Identify Psychological Seizures 2Health News:Clues To Identify Psychological Seizures 3
... and Fracture Table is a mobile, ... flexible, easy to use, articulated posturing ... orthopedic procedures. Radiolucent abductor bars, wedge-shaped ... exceptional imaging capability. OrthoVision folds into ...
... Field (PEMF) bone growth stimulation delivered by ... long bone and small bone nonunions. Physio-Stim ... brace, or clothing without lessening its effectiveness. ... compact, lightweight unit including success rates as ...
... implanted bone growth stimulator is a useful adjunct ... already planned or when patient compliance may be ... implanted, patients are assured of therapeutic treatment directly ... for up to 6 months. , ,The OsteoGen ...
Cannulated Interference Screws...
Medicine Products: